Carlsmed reported second quarter 2026 revenue of $18.9 million, reflecting a 57% year-over-year increase. This growth, coupled with a raised full-year guidance of $74 to $78 million, positions the company favorably in the AI-enabled spine surgery market.
Key Highlights
- Carlsmed, Inc. (NASDAQ: CARL) announced a strong second quarter 2026, reporting revenue of $18.9 million, which marks a remarkable 57% increase from $12.1 million in the same period last year.
- Carlsmed's latest earnings reflect the company's commitment to expanding its AI-enabled personalized spine surgery solutions.
- The anticipated reimbursement changes present long-term growth opportunities for Carlsmed, reinforcing its position within the healthcare system.
Carlsmed, Inc. (NASDAQ: CARL) announced a strong second quarter 2026, reporting revenue of $18.9 million, which marks a remarkable 57% increase from $12.1 million in the same period last year. This strong performance signals heightened investor confidence and suggests that Carlsmed is gaining substantial traction in the competitive medical technology sector.
Impressive Growth Metrics
Carlsmed's latest earnings reflect the company's commitment to expanding its AI-enabled personalized spine surgery solutions. Year-over-year revenue rose significantly, with gross profit at $14.5 million, resulting in a gross margin of 76.8%, up from 73.4% a year earlier. Operating expenses increased to $25.6 million, primarily due to higher sales and marketing costs, increasing from $7.9 million to $11.9 million.
The trained surgeon user base expanded by over 60%, indicating a strong push in surgeon adoption for the company's aprevo® procedures, important for maintaining competitive advantage. These figures highlight both growth potential and operational challenges that investors need to consider.
Strategic Changes Fuelling Momentum
The anticipated reimbursement changes present long-term growth opportunities for Carlsmed, reinforcing its position within the healthcare system. Investors should monitor the implementation of these reimbursement codes closely, as they may significantly impact revenue streams going forward.
Future Developments to Monitor
Carlsmed's performance will be further scrutinized during its upcoming conference call scheduled for August 5, where management is expected to provide in-depth insights into their operational strategy and market outlook. Featuring strong volume growth across both lumbar and cervical aprevo® offerings, this call will likely clarify operational scalability and advances in digital production as it prepares for increased market demand. Investors should pay close attention to any updates on market penetration strategies and continued user engagement as the company transitions into the latter half of 2026.
Analysis based on the Form 8-K filed 5 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...